KRYSTAL BIOTECH INC. - COMMON STOCK

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

18 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

08 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

01 Aug 2022 17:39:37 By Nasdaq GlobeNewswire

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

06 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

07 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

19 May 2022 18:30:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

09 May 2022 15:15:00 By Nasdaq GlobeNewswire

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

03 May 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

11 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

28 Mar 2022 10:00:00 By Nasdaq GlobeNewswire

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

26 Mar 2022 11:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

24 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

18 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Settlement with PeriphaGen, Inc.

15 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

24 Feb 2022 06:00:03 By Nasdaq GlobeNewswire

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

18 Jan 2022 06:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

30 Nov 2021 19:15:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

29 Nov 2021 15:20:00 By Nasdaq GlobeNewswire